How I Treat Acute Lymphoblastic Leukemia?

In order to receive the certificate of participation, you are required to fill out the registration form.

Registration link

Saturday, June 26th

19:30 (Tehran Time)

15:00 (GMT)

Join Zoom Meeting

Meeting ID: 937 5557 7881
Passcode: TUMS


English Guideline

Persian Guideline

Persian Zoom Help

Dr. Ashkan Emadi

Professor Of Medicine and Pharmacology, Associate Director for Clinical Research at University of Maryland, Greenebaum Comprehensive Cancer Center, Director of Translational Genomics Laboratory, University of Maryland School of Medicine, USA

Dr. Emadi is a hematologist/medical oncologist and an organic chemist; he is a Professor of Medicine and Pharmacology at the University of Maryland School of Medicine, and Marlene & Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). He has served as a medical officer at the Division of Hematology Products (DHP), United States Food and Drug Administration (FDA).

As an organic chemist, Dr. Emadi's breakthrough invention of using hydroxyquinone anion as active methylene to form a chemical bond between two SP2 carbons in quinone systems accelerated high yield synthesis of anti-neoplastic and anti-microbial medicinal compounds worldwide. As a molecular pharmacologist, he was the first to report that in adults with acute myeloid leukemia (AML) plasma glutamine (Gln) can safely be depleted to an undetectable level with promising anti-leukemic effect.

In his lab, Dr. Emadi directs cutting-edge translational patient-centered research focused on exploiting cancer metabolism particularly the glutamine dependency of cancers. His discovery of the combination of venetoclax (Ven) and pegcrisantaspase (PegC) as a novel, well tolerated and highly active regimen in vivo for the treatment of AML with a complex karyotype is potentially paradigm shifting for the treatment of poor risk AML. Clinically, Dr. Emadi is completely involved in the care of his patients. Through his time attending on inpatient leukemia service and his busy outpatient clinic, he sees > 2000 patient visits per year.

Education and mentorship remain cornerstones of Dr. Emadi's professional mandate. During his tenure of program director for UMGCCC hematology/oncology fellowship program, he expanded the size of the program and implemented curricular updates and strengthened faculty research mentoring to stimulate additional scholarly activity for the trainees. The University of Maryland Hematology/Oncology program is now highly sought out among applicants nationally. Dr. Emadi has mentored numerous clinical/research post-doctoral fellows, who now hold independent faculty positions. He is the Founder and the Presenter of popular Baltimore Oncopharmacology Lecture Series "Pharmacology of Chemotherapeutic Agents from Nitrogen Mustard to Modern Immunotherapies".

As UMGCCC's associate director for clinical research, Dr. Emadi oversees all clinical research activities and has scientific and administrative oversight of the Clinical Protocol & Data Management (CPDM) group, the Protocol Review and Monitoring System (PRMS) and the Early Phase Clinical Research Support enterprise. He creates strategic planning of clinical research initiatives and guides implementation of standard operating procedures. He formulates initiatives to enhance enrollment, especially of underrepresented minorities, in clinical trials.

Dr. Mazyar Shadman, MD, MPH

Associate Professor of Medical Oncology at Fred Hutchinson and University of Washington, USA



Dr. Marjan Yaghmaie

Associate Professor, Head of Leading House for Iran-North America Academic Partnerships, Tehran University of Medical Sciences, Iran



How I Treat Hematologic Malignancies Series: